Hello everyone 👋 Welcome to our new series #MeetTheLabMembers! We're thrilled to share with you who we are and what we do in our research lab. Join us on this journey to get to know our talented team!

👨‍🎓📄 3rd PhD from my #sarcoma lab at @VHIO Congratulations to Dr. David Gómez-Peregrina @dgomezpere 📣 Stay tuned to his terrific computational work on #GIST - sending out soon-ish!

🧐Willing to stay tuned for the latest advances and upcoming efforts in #ClinicalTrials in #Sarcomas? Check this review nicely arranged by @DiegoAGomez1 @Serrano_Lab and colleagues from @VHIO @vallhebron just out of the oven 🔥 ➡️ https://t.co/eb4pm9IQR8

Targeted Next-Generation Sequencing in Succinate Dehydrogenase–Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway: https://t.co/G9dIhBovsK #GastrointestinalCancer #gicsm Co-authored by @drcesarcoma, @carlomcicala and @serrano_lab

‼️mTOR and/or PI3K inhibitors can be an effective treatment in #GIST SDH-deficient 🧬Activating mutations in the PI3K/mTOR pathway in relapsed/mts samples 💊Sustained 55-months response with everolimus 🧐We provide other insights on tumor evolution 📰 https://t.co/2DgkDITocJ

Check it out!: https://t.co/xyYRuu9yHe @DrCeSarcoma @carlomcicala @dgomezpere @VHIO @Genomicslab_

🚨 New Publication Alert! 🚨 Our latest study, "Targeted Next-Generation Sequencing in Succinate Dehydrogenase-Deficient GI Stromal Tumor Identifies Actionable Alterations in the PI3K/mTOR Pathway," highlights the potential of NGS to uncover key mutations in SDH-deficient GIST.

🤩¡Empezamos 2025 con buenas noticias!: abrimos en el @VHIO el ensayo Fase II OSTEOMYC para investigar lel inhibidor de Myc OMO-103 en pacientes con #osteosarcoma que tengan 12 años o más. Gracias a @OSInstitute y @peptomyc por hacerlo posible Info➡️ https://t.co/pDDg5WypxU

💙 ¡Gracias, Asociación Iker‼️ Por vuestro compromiso en la investigación del #LiposarcomaMixoide que se lleva a cabo en el Grupo de Investigación Traslacional que dirige @DrCeSarcoma. ➕ https://t.co/g5u7cbfnDU

Meet Francesca! @FraEsposito2509 has joined our laboratory from Pavia, Italy, for a three-month stay. She will study the role of DNA damage in sarcomas during her time here.

Happy Sant Jordi from the Sarcoma laboratory members! 🐉🌹 @VHIO

@VHIO @TxellRovira @GrupoGeis @asargasarcoma @vallhebron

Yesterday, our group leader @DrCeSarcoma was awarded a @criscancer "Program of Excellence" award. We are very happy and looking forward to continue our research in GIST and sarcomas! #SarcomaResearch

Link:

Today @carlomcicala presented the paper "Optical Genome Mapping for Comprehensive Cytogenetic Analysis of Soft-Tissue and Bone Tumors for Diagnostic Purposes" in our journal club @KU_Leuven

➖Cytotoxic therapies, like platinum-based ones, can lead to secondary tumors in children. ➖Platinum therapies induce more mutations in children's normal tissues per day than aging does, underscoring the lasting impact of cytotoxic treatments on mutational burden.

Today @jonanderaguirre presented this paper by @guixe_m and colleagues in our #JournalClub Main conclusions: ➖ Pediatric cancers can lead to the development of second malignancies in children, and the origins of these second malignancies can vary.

Today @carlomcicala's family sent us two typical easter dishes from Naples: Casatiello and Pastiera. Buon appetito!

6/ She loves music, so in her free time she tries to go to as many concerts as she can. She also enjoys reading, movies, theater and above all, traveling.

5/ When asked about her motivations to continue contributing to the field, she expressed that her primary drive in the realm of oncology clinical trials is to assist those in greatest need and contribute significantly to cancer research.

4/ The project she works on aims to determine the clinical benefit of new therapies and mechanisms in sarcoma patients. She collects clinical and molecular variables from patients and analyzes relationships between molecular profile, sarcoma subtype and different drugs.